Brief: Tonix Pharmaceuticals Announces Positive Pre-NDA Meeting With FDA For Tonmya For The Management Of Fibromyalgia
20/06/2024 13:29
June 20 (Reuters) - Tonix Pharmaceuticals Holding Corp
TNXP.O :
* TONIX PHARMACEUTICALS ANNOUNCES POSITIVE PRE-NDA CMC
MEETING
WITH FDA FOR TONMYA™ FOR THE MANAGEMENT OF FIBROMYALGIA
* TONIX PHARMACEUTICALS HOLDING CORP: ON TRACK TO SUBMIT NDA
TO
FDA IN SECOND HALF OF 2024
* TONIX PHARMACEUTICALS HOLDING CORP: COMPLETED SECOND AND
FINAL
PRE-NEW DRUG APPLICATION MEETING
Source text for Eikon: ID:nGNX6Klc1p
Further company coverage: TNXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview